Suboptimal Vitamin D Status Is Associated with Salmonella Infection and Elevated C-Reactive Protein in Hospitalized Children with Acute Gastroenteritis: A Retrospective Cohort Study
Abstract
Background: Vitamin D contributes to intestinal barrier integrity and innate immune regulation, but its role in susceptibility to Salmonella infection and systemic inflammation in hospitalized pediatric patients with acute gastroenteritis (AGE) remains unclear. Methods: We retrospectively analyzed 70 pediatric patients hospitalized with AGE, examining the associations of admission 25(OH)D levels with culture-confirmed Salmonella infection and C-reactive protein (CRP). Multivariable logistic and linear regression models were adjusted for age and sex. Vitamin D status was classified as sufficient (≥30 ng/mL), suboptimal (<30 ng/mL), or deficient (<20 ng/mL). Results: The median age of the 70 included patients was 3.0 years (IQR: 1.5–6.0, range: 1.0–17 years), and 55.7% were male. Suboptimal vitamin D status was present in 64.3% of patients and was associated with higher median CRP levels (3.84 vs. 1.42 mg/dL, p = 0.025) and a greater prevalence of Salmonella infection (48.9% vs. 24.0%, p = 0.047). In multivariable analysis, suboptimal 25(OH)D levels independently marginally predicted an increased odds of Salmonella infection (adjusted odds ratio 3.11, 95% CI 1.00–9.67; p = 0.051). Serum 25(OH)D levels were inversely associated with natural log-transformed CRP (p = 0.026), with each 1 ng/mL increase corresponding to an estimated 5% reduction in CRP. Furthermore, vitamin D deficiency (<20 ng/mL) was associated with a 3.5-fold increase in CRP compared to levels ≥ 20 ng/mL (p =…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 70 participants or records.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.